GRAL’s Galleri Cancer Test Clears FDA Panel Safety Vote, Splits On Effectiveness

A U.S. Food and Drug Administration (FDA) advisory panel on Wednesday backed GRAIL’s Galleri multi-cancer blood test for adults aged 50 and older, voting that it looks safe and that its benefits outweigh its risks, while splitting 6-4 on effectiveness.The stock was on a trading halt during the comm…